Medical marijuana, what are we talking about?
PDF em inglês: https://doi.org/10.47626/1516-4446-2022-2608
DOI:
https://doi.org/10.25118/2763-9037.2022.v12.333Keywords:
Cannabinoids, Drug effects, Medical Marijuana, decriminalization of marijuana, public health, psychiatryAbstract
The term “medicinal marijuana” can be understood as a marketing strategy to reduce the risk perception of drug use. The medicinal use of cannabinoids is a debate that has gained importance in this representation space and presents a scientific issue as a scenario to bring the exam. The point of cannabidiol is not new, and its use and efficacy have been controversial. The therapeutic potential has been used as a false argument for the legalization of the use and cultivation of marijuana, with all its compounds. Nowadays, there are no cannabinoids approved for psychiatric indications. The dissemination of scientific information to avoid misperceptions and achieve a clear differentiation among the use of Cannabis in some diseases, in the wellness industry, and the consequences of non-medical use of marijuana should be done. Public policies should be focused on raising awareness about the potentially harmful effects associated with the use of marijuana by the general population. Also, higher investments in scientific research to investigate health damages of the non-medical use of marijuana are needed, as well as a better definition of the health conditions where products derived from Cannabis can be employed as an effective treatment.
Downloads
Metrics
References
Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Malka Stohl, Galea S, Wall MM. US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017 Jun; 74(6): 579–610. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2619522
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. Am J Psychiatry. 2022 Feb; 179(2):98-109. https://doi.org/10.1176/appi.ajp.2021.21030320
World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). https://www.unodc.org/unodc/data-and-analysis/wdr2021.html
Testai FD, Gorelick PB, Aparicio HJ, Filbey FM, Gonzalez R, Gottesman RF, Melis M, Piano MR, Rubino T, Song SY; on behalf of the American Heart Association Stroke Brain Health Science Subcommittee of the Stroke Council; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Use of marijuana: effect on brain health: a scientific statement from the American Heart Association. Stroke. 2022 Feb; 53:e1-e12.
http://doi.org/10.1161/STR.0000000000000396
Ganesh S, D’Souza DC. Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”. Am J Psychiatry. 2022; 179(1):8-10. https://doi.org/10.1176/appi.ajp.2021.21111126
Kessler FH, von Diemen L, Ornell F, Sordi AO. Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment. Braz J Psychiatry. 2021;43:455-457. http://dx.doi.org/10.1590/1516-4446-2021-1838
Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC n° 327, de 9 de dezembro de 2019, dispõe sobre os procedimentos para a concessão da Autorização Sanitária para a fabricação e a importação, bem como estabelece requisitos para a comercialização, prescrição, a dispensação, o monitoramento e a fiscalização de produtos de Cannabis para fins medicinais, e dá outras providências. Diário Oficial da União, Poder Executivo, Brasília, DF, 11 de dez. 2019. https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-rdc-n-327-de-9-de-dezembro-de-2019-232669072
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Dec; 6(12):995-1010. https://doi.org/10.1016/S2215-0366(19)30401-8
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
Copyright (c) 2022 César Augusto Trinta Weber, Antonio Geraldo da Silva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
